Overland ADCT BioPharma Reports the NMPA Acceptance of BLA and Granted Priority Review for Zynlonta for Diffuse Large B-cell Lymphoma
Shots:
- The NMPA has accepted and granted priority review to the BLA of Zynlonta for the treatment of adult patients with r/r DLBCL after two or more lines of systemic therapy in China. The product is expected to be available to Chinese r/r DLBCL patients shortly
- The application was based on the P-II bridging clinical trial (OL-ADCT-402-001) results evaluating the efficacy and safety of Zynlonta as monotx.
- Additionally, Overland ADCT BioPharma retains an exclusive right to develop and commercialize Zynlonta in Greater China and Singapore. Zynlonta was approved by the US FDA and EMA for the treatment of adult patients with r/r large B-cell lymphoma
Ref: Globenewswire | Image: Overland ADCT BioPharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
